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Shared mechanisms among probiotic taxa: implications
for general probiotic claims
Mary Ellen Sanders1, Andrew Benson2, Sarah Lebeer3,
Daniel J Merenstein4 and Todd R Klaenhammer5
Strain-specificity of probiotic effects has been a cornerstone
principle of probiotic science for decades. Certainly, some
important mechanisms are present in only a few probiotic
strains. But scientific advances now reveal commonalities
among members of certain taxonomic groups of probiotic
microbes. Some clinical benefits likely derive from these shared
mechanisms, suggesting that sub-species-specific, species-
specific or genus-specific probiotic effects exist. Human trials
are necessary to confirm specific health benefits. However, a
strain that has not been tested in human efficacy trials may
meet the minimum definition of the term ‘probiotic’ if it is a
member of a well-studied probiotic species expressing
underlying core mechanisms and it is delivered at an effective
dose.
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Introduction
Probiotics are live microorganisms that, when adminis-
tered in adequate amounts, confer a health benefit on the
host [1]. Probiotics span a wide range of uses, including
different regulatory categories, different target host spe-
cies, and different routes of administration (oral, in-
travaginal, topical) (Figure 1). The strain-specificity of
probiotic effects has been accepted for decades as a
fundamental principle based on mechanistic research
by scientists in the field. Today, it is rare to see
commercial products that do not list strain designations
or to read a clinical trial that does not identify the
probiotic to the strain level. Globally recognized guide-
lines have reinforced this concept [2].
Here we examine the concept that shared mechanisms
exist among taxonomic groups that include many differ-
ent strains (Figure 2). This concept was introduced
previously [1,3], but here we expand on the mechanis-
tic evidence to support this concept. Studies have shown,
and continue to show, that certain types of live micro-
organisms are beneficial to human health as assessed
through a range of digestive health endpoints. The num-
ber of tested strains is large and the range of health
benefits demonstrated is wide. We explore the signifi-
cance of these observations in the context of science-
based, responsible communication of health benefits of
probiotics to consumers and healthcare providers. We
focus on examples of Lactobacillus and Bifidobacterium,
because these are the traditionally used probiotics, but
the concepts are also valid for the next generation of
probiotics [4].
Shared mechanisms, shared benefits:
mechanistic rationale
In the probiotic field, it is clear that not all probiotics
function in the same manner. For example, the specific
bacteriocin produced by Lactobacillus salivarius UCC118,
which conferred resistance to Listeria monocytogenes infec-
tion when expressed in a mouse model [5], has not been
found in other strains of L. salivarius [6]. However, it is
equally clear that not all probiotic strains function in a
purely unique manner. As we discuss more completely
below, the ability to produce short chain fatty acids
(SCFAS) is a feature shared by many different probiotic
taxa, and surely plays a significant role in probiotic-medi-
ated health benefits. Consider the body of research con-
ducted on clinical effects of probiotics for prevention of
necrotizing enterocolitis: many taxa have been tested,
most of which resulted in similar clinical outcomes [7],
supporting the conclusion that probiotics from different
taxa have benefits in necrotizing enterocolitis. Here
we provide examples of mechanisms, which likely play
important roles in directing probiotic health benefits,
that have been identified among strains within probiotic
taxa. In some cases the traits may be shared broadly,
among most strains in a genus. In other cases, the distri-
bution of the mechanism may be much narrower. When
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mechanisms important to the expression of a health
benefit are shared, shared health benefits may result.
Bifidobacterium shunt and short chain fatty acid
production
The genus Bifidobacterium contains species that are gen-
erally known for their ability to degrade complex carbo-
hydrates and metabolize the derived monomers through a
shared central metabolic pathway known as the Bifido-
bacterium shunt (Bif Shunt). This pathway depends on
key enzymatic steps catalyzed by a phosphoketolase
enzyme that degrades hexose and pentose phosphates.
A unique feature of the Bif Shunt pathway is its increased
capacity for energy harvest from five- and six-carbon
sugars, which generally yields one additional ATP per
every two molecules of glucose compared to pathways
in other organisms [8]. Reliance of Bifidobacterium spe-
cies on the Bif Shunt pathway as a central metabolic
resource likely reflects an evolutionary adaptation in
Bifidobacterium that confers a fitness advantage during
natural colonization.
In addition to energy generation, the Bif Shunt pathway
yields SCFA as end products, specifically, lactate and
acetate (two moles of lactate and three moles acetate per
two moles of glucose) [8]. Increases in fecal SCFAs have
been observed in studies that administer probiotic species
of Bifidobacterium as well as studies where prebiotics are
used to stimulate abundances of native colonizing Bifi-
dobacterium species [9–12]. These SCFAs have a broad
array of positive effects on the human GI tract, either
directly or by conversion to other SCFA such as butyrate
by other members of the microbiota [13,14,15,16]. These
positive effects are mediated through multiple SCFA
receptors on colonocytes that directly control energy
and non-energy dependent motility and electrolyte trans-
port [17–21]. Beyond the transport and contractile func-
tions, SCFAs can also influence local inflammation by
affecting synthesis of inflammatory cytokines, inhibiting
208 Food biotechnology
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Probiotics: what is encompassed under this term (updated from Hill et al. [1]). By definition, a health benefit must be demonstrated for a
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synthesis of TNF-alpha and IL-6 and stimulating syn-
thesis of the anti-inflammatory cytokine IL-10 in macro-
phage and neutrophils [22–25]. These effects improve
inflammatory tone and have added to earlier interest in
incorporating SCFAs into anti-inflammatory enemas and
dietary SCFA-stimulating prebiotics as treatments in
patients with inflammatory bowel disease [26–30].
Comparative genomic analysis of publically available
Bifidobacterium genomes reveals that all thirteen enzymes
that comprise the Bif Shunt pathway are among the
core set of 480 genes shared across all species of
Bifidobacterium. This finding implies that the pathway
is ancestral to the common ancestor of extant Bifidobac-
terium species and strains. If this pathway indeed provides
a fitness advantage for growth of Bifidobacterium species in
the GI tract, it is reasonable to suspect that signatures of
such an evolutionary adaptation would be observable in
phylogeny of the Bif Shunt enzymes, particularly the
key phosphoketolase Xfp, which encodes a bifunctional
fructose-6-phosphate/xylulose-5-phosphate phosphoke-
tolase. Phylogenetic analysis of the Xfp phosphoketolase
from several species and strains of Bifidobacterium, along
with phosphoketolases from other members of the Phy-
lum Actinobacteria, as well as members of the Firmicutes,
Proteobacteria, and Cyanobacteria supports this hypothesis.
As illustrated from the unrooted dendrogram in Figure 3,
the Xfp proteins from the family Bifidobacteraceae (Bifi-
dobacterium, Scardovia, Gardenella) form a very distinct
cluster, with long branch length (greater genetic dis-
tance), distinctively separating this cluster from other
members of the Actinobacteria, a result that would be
expected if Xfp has undergone evolutionary adaptation.
The shared ancestry of the Bif Shunt pathway in Bifido-
bacterium species, the potential fitness advantage for
colonization, and the shared benefits of SFCAs produced
from this pathway provide support for a core benefit that
is shared across species. Although not addressed in detail
here, in a similar vein Lactobacillus species share key
metabolic traits since they predominately derive energy
through fermentation of sugars into lactic acid, via either
homofermentative or heterofermentative pathways, which
also cluster in separate phylogenetic clades [31].
Probiotic cell surface architecture
Flooding the upper small intestine with ingested Gram-
positive bacteria ( 1089/gm) temporarily overwhelms
the resident population (1047/cm2) during the transient
passage of microbes through the GI-tract. Because of
the dynamic changes constantly occurring in the mucosal
surface of the small intestine, such as variable mucin
production and accumulation, orally delivered microbes
are more likely to have greater access to the intestinal
mucosa, microvilli, Peyer’s Patches, and dendritic cells
signaling the immune system.
Important core mechanisms that underlie common pro-
biotic functions are found in the shared architecture of the
cell surface structures of Gram-positive microbes. Clearly,
not all Gram-positive microbes expressing these traits
are necessarily probiotics or beneficial. But when these
mechanisms are distributed among certain taxa known to
be probiotics, they may contribute to certain health
benefits in a somewhat predictable manner. These shared
architectures vary considerably among species and likely
impact the host’s physiological responses to beneficial
microbes that are either delivered orally or applied spa-
tially. These core cell surface architectures found among
species of Gram-positive bacteria are: peptidoglycan; cell
wall teichoic and lipoteichoic acid (LTA); and common
but varying components including exopolysaccharides,
surface layer associated proteins (SLAPS), mucin-binding
proteins (MUBs), fibronectin binding proteins, and pili.
These bacterial cell surface macromolecules are key
factors in this beneficial microorganism-host crosstalk,
as they can interact directly with the intestinal epithe-
lium, mucus, and host pattern recognition receptors of the
gastrointestinal mucosa.
Mucus-binding, fibronectin-binding and pilin proteins
The sortase pathway is the most common mechanism to
transport, deliver and link extracellular proteins to the
surface of Gram-positive bacteria [32]. This mechanism
underlies the presentation of MUBs, with their repeated
mucus-binding domains (reviewed by Etzold et al. [33]).
Linkage of MUBs to the peptidoglycan cell wall occurs
via a conserved Leu-Pro-any-Thr-Gly motif. First recog-
nized and characterized in Lactobacillus reuteri, MUBs are
widely distributed among commensal and probiotic lac-
tobacilli and bifidobacteria [33]. Genetic knockouts of
MUB proteins result in loss of mucin binding ability and
shorter retention times during transit through the mam-
malian GI-tract [34,35].
Sortase-dependent, cell surface pili have also been
defined in both lactobacilli (rhamnosus and ruminus
[36]) and bifidobacteria (bifidum, longum, dentium, adoles-
centis and lactis [37]). Close interaction with the intestinal
mucosa and mucin binding are key attributes commonly
exhibited by these pilin-like appendages. Mucin binding
via MUB’s and pili are considered key mechanisms
of ‘core’ probiotic activity that impacts retention in the
GI-tract, competitive exclusion of pathogens [38], immu-
nomodulation and structural integrity of the intestinal
mucosa. For instance, the sortase-dependent SpaCBA pili
of the model probiotic L. rhamnosus GG promote human
intestinal retention [36], competitive exclusion with the
pathogen Enterococcus faecium having similar mucus-binding
pili [38] and immunomodulation in macrophages [39]. In
addition, certain pili such as these glycosylated SpaCBA
pili of L. rhamnosus GG, also more specifically modulate
immune responses via special PRRs such as the DC-SIGN
receptor of dendritic cells [40]. Although improved
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persistence of a probiotic does not necessarily lead to a
health benefit, it provides an increased opportunity for a
probiotic to interact with its host.
Fibronectin-binding proteins
Fibronectin is a multi-domain glycoprotein found ubiq-
uitously in human body fluids and extracellular matrices
of a variety of mammalian tissues, including intestinal
epithelial cells. Fibronectin-binding proteins (FnBPs)
have been identified and characterized in a wide variety
of host-associated bacteria, including both pathogens
and commensals [41]. Colonization or retention in the
GI-tract highlights the role of multiple adhesions,
including FnBP’s. FnBP’s are core adhesions found
among Gram-positive commensals and probiotics and
found in L. acidophilus (S-layer associated — see below),
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and the non-S-layer producing species of L. casei,
L. plantarum, L. brevis and L. rhamnosus.
Surface-layer proteins
Another widely used commercial probiotic species,
L. acidophilus, produces an extracellular crystalline pro-
tein (SlpA) that creates a surface layer. These types of
proteins coat the cell surface of lactobacilli taxonomi-
cally assigned to the Lactobacillus acidophilus group
A; including L. acidophilus, L. helveticus, L. crispatus,
L. amylophilus, L. gallinarum, L. jensenii, L. kefiranofaciens
and L. amylovorus. In recent studies with L. acidophilus, it
has been discovered that multiple SLAPs exist (20–40)
and are loosely embedded within the major crystalline
surface layer protein, SlpA [42]. They likely act as
extracellular cell surface proteins able to interact with
mucosal tissues, and exert significant physiological,
enzymatic and immunological consequences. One nota-
ble example is that the fibronectin binding protein of
L. acidophilus is a SLAP [41]. SLAP proteins vary among
Lactobacilllus species, and are absent from species lack-
ing an S-layer; notably the probiotic species of L. gasseri,
L. johnsonii, L. reuteri, and L. (para)casei [43]. Yet certain
probiotic Lactobacillus species clearly produce the major
surface layer proteins (which alone have physiological
and immunological responses), and these S-layers also
embed loosely associated proteins that may intimately
interact with the intestinal mucosa. Thus, both S-layer
proteins and SLAPs represent a collection of proteins
that likely elicit common core mechanism for this bac-
terial group.
Peptidoglycan and lipoteichoic acid
During probiotic administration, a high dose of microbial-
associated molecular patterns (MAMPs) is consumed,
which can all interact with host PRRs resulting in various
immunomodulatory effects. Toll-like receptors (TLRs)
are the best documented PRRs being able to detect
various probiotic MAMPs. Since the most common pro-
biotic taxa are Gram-positive bacteria, TLR2 is a key
PRR because peptidoglycan and LTA are documented
MAMPs (reviewed in [44]). The core molecular archi-
tecture of peptidoglycan and LTA is well conserved
among lactobacilli — and bifidobacteria (e.g. [45]).
TLR2 has an important barrier-protective function in
intestinal epithelial cells [46]. Positively impacting intesti-
nal barrier function is a major probiotic mechanism [47].
However, it should be noted that — although Lactobacillus
LTA is a well-documented MAMP interacting with
TLR2/6 heterodimers [48], immunostimulation by LTA
of lactobacilli should be carefully taken into account, for
instance for applications in inflammatory bowel disease.
Modification of LTA [49] or removal of LTA [50] have
elicited significant anti-inflammatory consequences ob-
served in mouse models of both colitis and colon cancer.
In this case, the core mechanism is that probiotic Gram-
positive microbes with reduced expression of LTA are
more likely to modulate the anti-inflammatory immuno-
logical consequences that affect inflammatory bowel dis-
eases (as also reviewed in [51]).
Multiple other MAMP-PRR interactions between pro-
biotic bacteria and host cells can also occur and impact
on the final host responses. Inside the probiotic bacterial
cells, unmethylated cytosine-guanine (CpG)-containing
DNA is an important ligand for TLR9. TLR9 is
expressed by many cell types located in the intestine,
including epithelial cells and classical immune cells.
TLR9 signaling is also important for gut epithelial
homeostasis. Recently, a bioinformatics analysis was per-
formed on the frequency of potentially immunostimula-
tory CpG motifs in the genomes of gut commensal
bacteria across major bacterial phyla [52]. The frequency
of these motifs (all hexamers) was linearly dependent on
the genomic G + C content: species belonging to Proteo-
bacteria, Bacteroidetes and Actinobacteria (including
bifidobacteria) carried high counts of GTCGTT, the
optimal motif stimulating human TLR9. However,
despite having an A + T rich genome content, Lactoba-
cillus casei, Lactobacillus plantarum and Lactobacillus
rhamnosus strains that have been marketed as probiotics
were found to have high counts of GTCGTT motifs.
Indeed, CpG-rich DNA from the widely used probiotic
strain L. rhamnosus GG has been shown to interact with
TLR9 on endosomes to stimulate Th1 responses
[53,54]. Not all probiotic immunomodulatory molecules
function through PRRs. For example, some widely
excreted enzymes seem to actively impact cytokine
activity, such as the conserved cell envelop associated
PrtP-proteases (also named lactocepin), which has been
shown to selectively degrade proinflammatory cytokines
[55]. In their recent large genome comparison of lac-
tobacilli, Sun et al. [56] also highlight these proteases as
potential probiotic factors, which show clear clade asso-
ciation, notably with the L. delbrueckii, L. casei and L.
buchneri clades, part of the L. salivarius clade, and the
Carnobacterium clade. The presence of this probiotic
feature is thus a nice example of a property existing
beyond the strain-specific dogma. Furthermore, several
bacterial metabolites such as the SCFAs mentioned
above and various aminoacids (e.g. trypthophan-derived
products), all can impact directly on the host immune
status (e.g. [57]). In line with these more ‘metabolic
modes of action’, the only ‘probiotic’ mechanism of
action currently approved in Europe by EFSA is
improved lactose digestion by live yoghurt cultures
containing at least 108 CFU/g Lactobacillus delbrueckii
subsp. bulgaricus and Streptococcus thermophilus, because
these bacteria are known to express the necessary
enzymes (lactase or beta-galactosidase) to degrade lac-
tose. Similarly, strains producing high levels of vitamins
(e.g. vitamin B12 by certain lactobacilli [58] and folate
by certain bifidobacteria [59]) are being selected that
produce enough to meet minimum daily requirements.
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Category-based evidence
Systematic reviews (SR) and meta-analyses (MAs) are
important tools for assessing the totality of evidence for a
given intervention. An essential component of the SR/
MA process is clear definition of the intervention being
researched. In the case of probiotics, over 200 meta-
analyses have been published and most of these have
not been conducted on individual strains. The implied
rationale for this is that the outcomes being studied are
expected to be expressed by many different strains.
Although the essence of this assumption may not be
clearly considered or even understood by many of the
authors of these SR/MAs, the rationale may be sound
[60]. To the extent that a common mechanism can be
described among a group of different strains, it is scien-
tifically sound to pool results on clinical outcomes on
those strains.
The process of assigning health benefits to a category,
rather than a defined entity, is not unique to the probi-
otic field. Fecal microbial transplant to prevent recur-
rent Clostridium difficile disease, an intervention widely
accepted in the medical community, is a case-in-point.
The fecal preparations are wholly undefined, vary by
donating host, are delivered in different manners, and
are undoubtedly immensely impacted by handling
practices, which surely take a toll on strict anaerobe
populations.
Other examples come from dietary recommendations.
The broad category of ‘dietary fiber’ is recommended
and fully endorsed, yet dietary fibers are a broad category,
differing in their structure and their physiological impact.
Perhaps resulting from the explosion of human micro-
biome research revealing the importance of live microbes
in human health, fermented foods have surged in popu-
larity. Fermented foods that retain their live microbial
constituents (i.e. have not been processed to kill or
remove the fermentation microbes) have been around
for millennia, but are being recognized anew for their
potential health benefits [61]. Fermented foods often
have a rich, undefined microbial content. The health
benefits due to the microbial components of these foods
are examples of expression of health promoting mecha-
nisms likely shared among many different taxa.
It is widely accepted that there are class effects of
medications, yet different medications comprise a
given class. For example, as a class all beta-adrenergic
blocking agents (beta blockers) work by blocking
receptor  sites epinephrine and norepinephrine result-
ing in a lower pulse rate and reduced blood pressure.
However, there are many differences among the vari-
ous beta blocking medications and they have a wide
range of indications. The same type of overall class
benefit is seen with 3-hydroxy-3-methylglutaryl coen-
zyme-A reductase inhibitors, proton pump inhibitors,
selective serotonin reuptake inhibitors and many other
drug classes.
Overall implications
Probiotic claims
Assuring that consumers are not misled is a common
objective among global agencies responsible for oversight
of health benefit claims on probiotic products. Preventing
unsubstantiated claims is a top priority. Unfortunately, at
times this can put a limit on consumer access to legitimate
information, with negative implications for the health of
adults and children around the world. One example is the
situation in the EU, which currently prohibits the use of
the word ‘probiotic’ on foods. As previously asserted [1],
consumers are not misled by products being labeled as
‘probiotic’ if the products contain adequate amounts of a
well-studied probiotic species documented in numerous
studies to confer a beneficial effect. This idea is rein-
forced through the common mechanistic properties of
probiotic taxa presented here. We provide the scientific
rationale and well-documented examples of mechanisms
for defining commonalities that exist for groupings of
individual strains. It is noteworthy that this approach
has been accepted by regulatory approaches in Canada
and Italy, and is consistent with the claim EFSA allowed
for the species Lactobacillus bulgaricus and Streptococcus
thermophilus [62].
Probiotic product labels
It should be emphasized that the evidence presented
herein does not eliminate the responsibility for research-
ers and commercial entities to continue to fully define and
disclose the content of probiotic products to the strain
level. Fermented foods, as indicated in Figure 1, to the
extent their microbial content is undefined, are not pro-
biotic products. But any product claiming to be a probiotic
must accurately disclose the levels of the microbes pres-
ent and identify them to the genus, species and strain
level, ideally including complete genome sequences.
Such disclosure is needed to assure product consistency,
transparency in marketing and the ability to repeat
research. Additionally, human studies with defined strains
and doses are necessary to support specific health benefit
claims.
Conclusion
In 2014, a consensus group of experts recommended to
‘Include in the framework for definition of probiotics
microbial species that have been shown in properly
controlled studies to confer benefits to health’ [1].
Although laboratory assessments document many ways
in which strains may differ [63], we lack direct evidence
on how different strains may utilize similar mechanisms
to exert similar clinical outcomes. Most clinical studies
do not compare multiple strains of the same species.
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However numerous meta-analyses show that similar clini-
cal benefits are achieved by many different strains [64].
It is not possible to assert with 100% confidence that the
presence of certain metabolic pathways or molecular
mechanisms will confer a given clinical benefit. A strain
may be deficient in overall physiological fitness or may
otherwise possess traits that override adequate expression
of encoded properties, which precludes detection of an
overall health benefit. However, as research continues to
evolve, associations between the presence of specific
mechanisms and clinical benefits will continue to
strengthen confidence. The net clinical effect of a live
bacterium will be dictated by the complex array of genetic
expression and technological production factors for pro-
biotic cultures that impact viability and shelf-life. Human
trials to confirm that a given mechanism drives the
observed clinical effects will improve our understanding.
The probiotic field would benefit from agreement among
experts regarding what constitutes adequate evidence of
assignment of a clinical benefit to a larger taxonomic
group.
We present here evidence for mechanisms that are shared
among probiotic taxonomic groups at higher levels than
strain. Although further research is needed to confirm the
link between a given mechanism and clinical benefit, we
propose that the distribution of such mechanisms among
all members of a taxon provides a rationale that some
general probiotic benefits can be expected in a non-
strain-specific manner.
Acknowledgements
The authors wish to acknowledge the International Scientific Association
for Probiotics and Prebiotics for driving this discussion and providing travel
funding for experts to convene and discuss this topic. Gratitude is also
expressed to Dr. Alexandra Mannerings for preparing Figures 1 and 2.
References and recommended reading
Papers of particular interest, published within the period of review,
have been highlighted as:
 of special interest
 of outstanding interest
1.

Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B,
Morelli L, Canani RB, Flint HJ, Salminen S et al.: Expert
consensus document. The International Scientific Association
for Probiotics and Prebiotics consensus statement on the
scope and appropriate use of the term probiotic. Nat Rev
Gastroenterol Hepatol 2014, 11:506-514.
Important consensus by group of experts in the field on updating the
2002 FAO/WHO probiotic definition and correct use of the term. The
concept of shared mechanisms dictating shared benefits at the species
or higher level is developed.
2. Food and Agricultural Organization of the United Nations and
World Health Organization: Joint FAO/WHO working group report
on drafting guidelines for the evaluation of probiotics in food. 2002.
3.

Hill C, Sanders ME: Rethinking “probiotics”. Gut Microbes 2013,
4:269-270.
The concept of shared mechanisms dictating shared benefits at the
species or higher level is proposed.
4. O’Toole PW, Marchesi JR, Hill C: Next-generation probiotics:
the spectrum from probiotics to live biotherapeutics. Nat
Microbiol 2017, 2:17057.
5. Corr SC, Li Y, Riedel CU, O’Toole PW, Hill C, Gahan CG:
Bacteriocin production as a mechanism for the antiinfective
activity of Lactobacillus salivarius UCC118. Proc Natl Acad Sci
U S A 2007, 104:7617-7621.
6. O’Shea EF, O’Connor PM, Raftis EJ, O’Toole PW, Stanton C,
Cotter PD, Ross RP, Hill C: Production of multiple bacteriocins
from a single locus by gastrointestinal strains of Lactobacillus
salivarius. J Bacteriol 2011, 193:6973-6982.
7. AlFaleh K, Anabrees J: Probiotics for prevention of necrotizing
enterocolitis in preterm infants. Cochrane Database Syst Rev
2014:CD005496.
8. O’Callaghan A, van Sinderen D: Bifidobacteria and their role as
members of the human gut microbiota. Front Microbiol 2016, 7.
9. Wang C, Shoji H, Sato H, Nagata S, Ohtsuka Y, Shimizu T,
Yamashiro Y: Effects of oral administration of bifidobacterium
breve on fecal lactic acid and short-chain fatty acids in low birth
weight infants. J Pediatr Gastroenterol Nutr 2007, 44:252-257.
10. Bird AR, Vuaran M, Crittenden R, Hayakawa T, Playne MJ,
Brown IL, Topping DL: Comparative effects of a high-amylose
starch and a fructooligosaccharide on fecal bifidobacteria
numbers and short-chain fatty acids in pigs fed
Bifidobacterium animalis. Dig Dis Sci 2009, 54:947-954.
11. Gargari G, Taverniti V, Balzaretti S, Ferrario C, Gardana C,
Simonetti P, Guglielmetti S: Consumption of a Bifidobacterium
bifidum strain for 4 weeks modulates dominant intestinal
bacterial taxa and fecal butyrate in healthy adults. Appl Environ
Microbiol 2016, 82:5850-5859.
12. Hald S, Schioldan AG, Moore ME, Dige A, Laerke HN, Agnholt J,
Bach Knudsen KE, Hermansen K, Marco ML, Gregersen S et al.:
Effects of arabinoxylan and resistant starch on intestinal
microbiota and short-chain fatty acids in subjects with
metabolic syndrome: a randomised crossover study. PLOS
ONE 2016, 11:e0159223.
13.

Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ,
Brummer RJ: Review article: the role of butyrate on colonic
function. Aliment Pharmacol Ther 2008, 27:104-119.
Excellent review on the many physiological effects of butyrate and why
this molecule is so important to human health.
14. Flint HJ, Bayer EA, Rincon MT, Lamed R, White BA:
Polysaccharide utilization by gut bacteria: potential for new
insights from genomic analysis. Nat Rev Micro 2008, 6:121-131.
15. Scheppach W: Effects of short chain fatty acids on gut
morphology and function. Gut 1994, 35:S35-S38.
16. Falony G, Vlachou A, Verbrugghe K, Vuyst LD: Cross-feeding
between Bifidobacterium longum BB536 and acetate-
converting, butyrate-producing colon bacteria during growth
on oligofructose. Appl Environ Microbiol 2006, 72:7835-7841.
17. Cherbut C: Motor effects of short-chain fatty acids and lactate
in the gastrointestinal tract. Proc Nutr Soc 2003, 62:95-99.
18. Havenaar R: Intestinal health functions of colonic microbial
metabolites: a review. Beneficial Microbes 2011, 2:103-114.
19. Cherbut C, Aube´ AC, Blottie`re HM, Galmiche JP: Effects of
short-chain fatty acids on gastrointestinal motility. Scand J
Gastroenterol Suppl 1997, 32:58-61.
20. Dass NB, John AK, Bassil AK, Crumbley CW, Shehee WR,
Maurio FP, Moore GB, Taylor CM, Sanger GJ: The relationship
between the effects of short-chain fatty acids on intestinal
motility in vitro and GPR43 receptor activation.
Neurogastroenterol Motil 2007, 19:66-74.
21. Tazoe H, Otomo Y, Kaji I, Tanaka R, Karaki SI, Kuwahara A: Roles
of short-chain fatty acids receptors, GPR41 and GPR43 on
colonic functions. J Physiol Pharmacol 2008, 59(Suppl 2):251-262.
22. Vinolo MAR, Rodrigues HG, Nachbar RT, Curi R: Regulation of
inflammation  by short chain fatty acids. Nutrients 2011, 3:858-876.
214 Food biotechnology
Current Opinion in Biotechnology 2018, 49:207–216 www.sciencedirect.com
23. Vinolo MAR, Rodrigues HG, Hatanaka E, Sato FT, Sampaio SC,
Curi R: Suppressive effect of short-chain fatty acids on
production of proinflammatory mediators by neutrophils.
J Nutr Biochem 2011, 22:849-855.
24. Park JS, Lee EJ, Lee JC, Kim WK, Kim HS: Anti-inflammatory
effects of short chain fatty acids in IFN-g-stimulated RAW
264.7 murine macrophage cells: involvement of NF-kB and
ERK signaling pathways. Int Immunopharmacol 2007, 7:70-77.
25. Maslowski KM, Vieira AT, Ng A, Kranich J, Sierro F, Di Y,
Schilter HC, Rolph MS, Mackay F, Artis D et al.: Regulation of
inflammatory responses by gut microbiota and
chemoattractant receptor GPR43. Nature 2009, 461:1282-1286.
26. Moreau NM, Martin LJ, Toquet CS, Laboisse CL, Nguyen PG,
Siliart BS, Dumon HJ, Champ MM: Restoration of the integrity of
rat caeco-colonic mucosa by resistant starch, but not by
fructo-oligosaccharides, in dextran sulfate sodium-induced
experimental colitis. Br J Nutr 2003, 90:75-85.
27. Hallert C, Bjorck I, Nyman M, Pousette A, Granno C, Svensson H:
Increasing fecal butyrate in ulcerative colitis patients by diet:
controlled pilot study. Inflamm Bowel Dis 2003, 9:116-121.
28. Saemann MD, Bohmig GA, Zlabinger GJ: Short-chain fatty acids:
bacterial mediators of a balanced host–microbial relationship
in the human gut. Wien Klin Wochenschr 2002, 114:289-300.
29. Kunzelmann K, Mall M: Electrolyte transport in the mammalian
colon: mechanisms and implications for disease. Physiol Rev
2002, 82:245-289.
30. Scheppach W, Christl SU, Bartram HP, Richter F, Kasper H:
Effects of short-chain fatty acids on the inflamed colonic
mucosa. Scand J Gastroenterol Suppl 1997, 222:53-57.
31. Duar RM, Lin XB, Zheng J, Martino ME, Grenier T,
Perez-Munoz ME, Leulier F, Ganzle M, Walter J: Lifestyles in
transition: evolution and natural history of the genus
Lactobacillus. FEMS Microbiol Rev 2017, 41:S27-S48.
32. Call EK, Klaenhammer TR: Relevance and application of sortase
and sortase-dependent proteins in lactic acid bacteria. Front
Microbiol 2013, 4:73.
33. Etzold S, Kober OI, Mackenzie DA, Tailford LE, Gunning AP,
Walshaw J, Hemmings AM, Juge N: Structural basis for
adaptation of lactobacilli to gastrointestinal mucus. Environ
Microbiol 2014, 16:888-903.
34. Call EK, Goh YJ, Selle K, Klaenhammer TR, O’Flaherty S:
Sortase-deficient lactobacilli: effect on immunomodulation
and gut retention. Microbiology 2015, 161:311-321.
35. Lebeer S, Claes I, Tytgat HL, Verhoeven TL, Marien E, von
Ossowski I, Reunanen J, Palva A, Vos WM, Keersmaecker SC
et al.: Functional analysis of Lactobacillus rhamnosus GG pili in
relation to adhesion and immunomodulatory interactions with
intestinal epithelial cells. Appl Environ Microbiol 2012, 78:185-193.
36. Kankainen M, Paulin L, Tynkkynen S, von Ossowski I, Reunanen J,
Partanen P, Satokari R, Vesterlund S, Hendrickx AP, Lebeer S
et al.: Comparative genomic analysis of Lactobacillus
rhamnosus GG reveals pili containing a human-mucus binding
protein. Proc Natl Acad Sci U S A 2009, 106:17193-17198.
37. Foroni E, Serafini F, Amidani D, Turroni F, He F, Bottacini F,
O’Connell Motherway M, Viappiani A, Zhang Z, Rivetti C et al.:
Genetic analysis and morphological identification of pilus-like
structures in members of the genus Bifidobacterium. Microb
Cell Fact 2011, 10(Suppl 1):S16.
38. Tytgat HL, Douillard FP, Reunanen J, Rasinkangas P,
Hendrickx AP, Laine PK, Paulin L, Satokari R, de Vos WM:
Lactobacillus rhamnosus GG Outcompetes Enterococcus
faecium via mucus-binding pili: evidence for a novel and
heterospecific probiotic mechanism. Appl Environ Microbiol
2016, 82:5756-5762.
39. Garcia V, Reyes-Darias JA, Martin-Mora D, Morel B, Matilla MA,
Krell T: Identification of a chemoreceptor for C2 and C3
carboxylic acids. Appl Environ Microbiol 2015, 81:5449-5457.
40. Tytgat HL, van Teijlingen NH, Sullan RM, Douillard FP,
Rasinkangas P, Messing M, Reunanen J, Satokari R,
Vanderleyden J, Dufrene YF et al.: Probiotic gut microbiota
isolate interacts with dendritic cells via glycosylated
heterotrimeric pili. PLOS ONE 2016, 11:e0151824.
41. Hymes JP, Klaenhammer TR: Stuck in the middle: fibronectin-
binding proteins in gram-positive bacteria. Front Microbiol
2016, 7:1504.
42. Johnson BR, Hymes J, Sanozky-Dawes R, Henriksen ED,
Barrangou R, Klaenhammer TR: Conserved S-layer-associated
proteins revealed by exoproteomic survey of S-layer-forming
lactobacilli. Appl Environ Microbiol 2015, 82:134-145.
43. Wuyts S, Wittouck S, De Boeck I, Allonsius CN, Pasolli E,
Segata N, Lebeer S: Large-scale phylogenomics of the
Lactobacillus casei group highlights taxonomic
inconsistencies and reveals novel clade-associated features.
mSystems 2017, 2.
44.

Lebeer S, Vanderleyden J, De Keersmaecker SC: Host
interactions of probiotic bacterial surface molecules:
comparison with commensals and pathogens. Nat Rev
Microbiol 2010, 8:171-184.
Nice review of probiotic mechanisms of action and how probiotics fit
within the microecology of the gut.
45. Colagiorgi A, Turroni F, Mancabelli L, Serafini F, Secchi A, van
Sinderen D, Ventura M: Insights into teichoic acid biosynthesis
by Bifidobacterium bifidum PRL2010. FEMS Microbiol Lett
2015, 362:fnv141.
46. Cario E: Barrier-protective function of intestinal epithelial Toll-
like receptor 2. Mucosal Immunol 2008, 1(Suppl 1):S62-S66.
47. Bron PA, Kleerebezem M, Brummer RJ, Cani PD, Mercenier A,
MacDonald TT, Garcia-Rodenas CL, Wells JM: Can probiotics
modulate human disease by impacting intestinal barrier
function? Br J Nutr 2017, 117:93-107.
48. Claes IJ, Segers ME, Verhoeven TL, Dusselier M, Sels BF, De
Keersmaecker SC, Vanderleyden J, Lebeer S: Lipoteichoic acid
is an important microbe-associated molecular pattern of
Lactobacillus rhamnosus GG. Microb Cell Fact 2012, 11:161.
49. Grangette C, Nutten S, Palumbo E, Morath S, Hermann C,
Dewulf J, Pot B, Hartung T, Hols P, Mercenier A: Enhanced
antiinflammatory capacity of a Lactobacillus plantarum
mutant synthesizing modified teichoic acids. Proc Natl Acad
Sci U S A 2005, 102:10321-10326.
50. Khazaie K, Zadeh M, Khan MW, Bere P, Gounari F, Dennis K,
Blatner NR, Owen JL, Klaenhammer TR, Mohamadzadeh M:
Abating colon cancer polyposis by Lactobacillus acidophilus
deficient in lipoteichoic acid. Proc Natl Acad Sci U S A 2012,
109:10462-10467.
51. Lebeer S, Claes IJ, Vanderleyden J: Anti-inflammatory potential
of probiotics: lipoteichoic acid makes a difference. Trends
Microbiol 2012, 20:5-10.
52.

Kant R, de Vos WM, Palva A, Satokari R: Immunostimulatory
CpG motifs in the genomes of gut bacteria and their role in
human health and disease. J Med Microbiol 2014, 63:293-308.
This paper surveys the distribution of microbe-associated molecular
patterns, specifically CpG motifs, among commensal bacteria, including
probiotic species. Authors make the case that CpG motif-rich DNA,
common among probiotic species, may drive the immune stimulatory
effects observed in many probiotic strains.
53. Iliev ID, Kitazawa H, Shimosato T, Katoh S, Morita H, He F,
Hosoda M, Saito T: Strong immunostimulation in murine
immune cells by Lactobacillus rhamnosus GG DNA
containing novel oligodeoxynucleotide pattern. Cell Microbiol
2005, 7:403-414.
54. Iliev ID, Tohno M, Kurosaki D, Shimosato T, He F, Hosoda M,
Saito T, Kitazawa H: Immunostimulatory oligodeoxynucleotide
containing TTTCGTTT motif from Lactobacillus rhamnosus
GG DNA potentially suppresses OVA-specific IgE production
in mice. Scand J Immunol 2008, 67:370-376.
55.

von Schillde MA, Hormannsperger G, Weiher M, Alpert CA,
Hahne H, Bauerl C, van Huynegem K, Steidler L, Hrncir T,
Perez-Martinez G et al.: Lactocepin secreted by Lactobacillus
exerts anti-inflammatory effects by selectively degrading
Shared core probiotic mechanisms Sanders et al. 215
www.sciencedirect.com Current Opinion in Biotechnology 2018, 49:207–216
proinflammatory chemokines. Cell Host Microbe 2012,
11:387-396.
This paper is a nice demonstration through knockout mutants of a gene
associated with a specific probiotic function in vivo. Anti-inflammatory
activity was found to be associated with the production of the protease
lactocepin made by Lactobacillus paracasei in a mouse model, and a
strain deficient in the gene encoding this protease lost its anti-inflam-
matory ability.
56.

Sun Z, Harris HM, McCann A, Guo C, Argimon S, Zhang W, Yang X,
Jeffery IB, Cooney JC, Kagawa TF et al.: Expanding the
biotechnology potential of lactobacilli through comparative
genomics of 213 strains and associated genera. Nat Commun
2015, 6:8322.
Lactobacillusis diverse genus phenotypically and phylogenetically. This
paper reports an expansive data set of mostly Lactobacillusgenome
sequences, enriching available databases with 179 new type strains.
This research provides the means to understand the distribution of traits
and mechanisms throughout the Lactobacillusgenus.
57. Correa-Oliveira R, Fachi JL, Vieira A, Sato FT, Vinolo MA:
Regulation of immune cell function by short-chain fatty acids.
Clin Transl Immunol 2016, 5:e73.
58. Li P, Gu Q, Yang L, Yu Y, Wang Y: Characterization of
extracellular vitamin B12 producing Lactobacillus plantarum
strains and assessment of the probiotic potentials. Food Chem
2017, 234:494-501.
59. Rossi M, Amaretti A, Raimondi S: Folate production by probiotic
bacteria. Nutrients 2011, 3:118-134.
60. Glanville J, King S, Guarner F, Hill C, Sanders ME: A review of the
systematic review process and its applicability for use in
evaluating evidence for health claims on probiotic foods in the
European Union. Nutr J 2015, 14:16.
61. Marco ML, Heeney D, Binda S, Cifelli CJ, Cotter PD, Foligne B,
Ganzle M, Kort R, Pasin G, Pihlanto A et al.: Health benefits of
fermented foods: microbiota and beyond. Curr Opin Biotechnol
2017, 44:94-102.
62. EFSA Panel on Dietetic Products NaA: Scientific Opinion on the
substantiation of health claims related to live yoghurt cultures
and improved lactose digestion (ID 1143, 2976) pursuant to
Article 13(1) of Regulation (EC) No 1924/2006. EFSA J 2010,
8:1763.
63. Foligne B, Deutsch SM, Breton J, Cousin FJ, Dewulf J, Samson M,
Pot B, Jan G: Promising immunomodulatory effects of selected
strains of dairy propionibacteria as evidenced in vitro and in
vivo. Appl Environ Microbiol 2010, 76:8259-8264.
64. Ritchie ML, Romanuk TN: A meta-analysis of probiotic efficacy
for gastrointestinal diseases. PLoS ONE 2012, 7:e34938.
65. Green JM, Barratt MJ, Kinch M, Gordon JI: Food and microbiota
in the FDA regulatory framework. Science 2017, 357:39-40.
66. Lemon KP, Armitage GC, Relman DA, Fischbach MA: Microbiota-
targeted therapies: an ecological perspective. Sci Transl Med
2012, 4:137rv135.
67. Dinan TG, Stanton C, Cryan JF: Psychobiotics: a novel class of
psychotropic. Biol Psychiatry 2013, 74:720-726.
68. Shanahan F, Collins SM: Pharmabiotic manipulation of the
microbiota in gastrointestinal disorders, from rationale to
reality. Gastroenterol Clin North Am 2010, 39:721-726.
216 Food biotechnology
Current Opinion in Biotechnology 2018, 49:207–216 www.sciencedirect.com
